Fellowship · Rochester, NY
Sponsored by University of Rochester Medicine
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
The New England journal of medicine · 2021 · 1,404 citations · Angela Branche
Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults.
The New England journal of medicine · 2023 · 550 citations · Edward E. Walsh, Ann R. Falsey
Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: A systematic literature review and meta-analysis.
Influenza and other respiratory viruses · 2023 · 329 citations · Angela Branche
Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults.
The New England journal of medicine · 2023 · 422 citations · Ann R. Falsey, Edward E. Walsh
Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.
American journal of respiratory and critical care medicine · 2025 · 112 citations · Sonal S. Munsiff
Efficacy, Immunogenicity, and Safety of the Bivalent Respiratory Syncytial Virus (RSV) Prefusion F Vaccine in Older Adults Over 2 RSV Seasons.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026 · 50 citations · Edward E. Walsh
SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection.
The New England journal of medicine · 2022 · 459 citations · Matthew Sims
Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024.
MMWR. Morbidity and mortality weekly report · 2024 · 183 citations · Geoffrey Weinberg